Kamada (KMDA) Competitors $6.47 -0.13 (-1.97%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KMDA vs. IMCR, KNSA, IRON, SPRY, EWTX, VERA, TVTX, GPCR, MESO, and EVOShould you be buying Kamada stock or one of its competitors? The main competitors of Kamada include Immunocore (IMCR), Kiniksa Pharmaceuticals (KNSA), Disc Medicine (IRON), ARS Pharmaceuticals (SPRY), Edgewise Therapeutics (EWTX), Vera Therapeutics (VERA), Travere Therapeutics (TVTX), Structure Therapeutics (GPCR), Mesoblast (MESO), and Evotec (EVO). These companies are all part of the "pharmaceutical products" industry. Kamada vs. Immunocore Kiniksa Pharmaceuticals Disc Medicine ARS Pharmaceuticals Edgewise Therapeutics Vera Therapeutics Travere Therapeutics Structure Therapeutics Mesoblast Evotec Kamada (NASDAQ:KMDA) and Immunocore (NASDAQ:IMCR) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, community ranking, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends. Is KMDA or IMCR more profitable? Kamada has a net margin of 9.92% compared to Immunocore's net margin of -15.87%. Kamada's return on equity of 6.30% beat Immunocore's return on equity.Company Net Margins Return on Equity Return on Assets Kamada9.92% 6.30% 4.49% Immunocore -15.87%-12.84%-5.09% Does the media refer more to KMDA or IMCR? In the previous week, Immunocore had 6 more articles in the media than Kamada. MarketBeat recorded 8 mentions for Immunocore and 2 mentions for Kamada. Immunocore's average media sentiment score of 1.31 beat Kamada's score of 1.10 indicating that Immunocore is being referred to more favorably in the news media. Company Overall Sentiment Kamada Positive Immunocore Positive Which has higher valuation and earnings, KMDA or IMCR? Kamada has higher earnings, but lower revenue than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than Kamada, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKamada$160.95M2.31$8.28M$0.2624.88Immunocore$310.20M4.86-$55.29M-$1.02-29.51 Which has more volatility and risk, KMDA or IMCR? Kamada has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. Comparatively, Immunocore has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500. Do institutionals and insiders believe in KMDA or IMCR? 20.4% of Kamada shares are held by institutional investors. Comparatively, 84.5% of Immunocore shares are held by institutional investors. 36.1% of Kamada shares are held by company insiders. Comparatively, 10.4% of Immunocore shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer KMDA or IMCR? Kamada presently has a consensus price target of $14.67, indicating a potential upside of 126.69%. Immunocore has a consensus price target of $59.44, indicating a potential upside of 97.49%. Given Kamada's stronger consensus rating and higher probable upside, equities research analysts clearly believe Kamada is more favorable than Immunocore.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kamada 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Immunocore 1 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.45 Does the MarketBeat Community prefer KMDA or IMCR? Kamada received 254 more outperform votes than Immunocore when rated by MarketBeat users. However, 73.47% of users gave Immunocore an outperform vote while only 66.26% of users gave Kamada an outperform vote. CompanyUnderperformOutperformKamadaOutperform Votes32666.26% Underperform Votes16633.74% ImmunocoreOutperform Votes7273.47% Underperform Votes2626.53% SummaryKamada beats Immunocore on 11 of the 18 factors compared between the two stocks. Get Kamada News Delivered to You Automatically Sign up to receive the latest news and ratings for KMDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KMDA vs. The Competition Export to ExcelMetricKamadaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$371.90M$6.90B$5.57B$7.82BDividend YieldN/A3.06%5.11%4.22%P/E Ratio23.117.4522.4218.48Price / Sales2.31242.72394.10103.91Price / Cash17.9065.8538.1834.62Price / Book1.526.516.774.25Net Income$8.28M$143.21M$3.22B$248.23M7 Day Performance-1.67%3.97%3.26%3.29%1 Month Performance-4.15%0.37%0.02%2.42%1 Year Performance23.95%2.60%18.01%5.54% Kamada Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KMDAKamada3.8825 of 5 stars$6.47-2.0%$14.67+126.7%+23.9%$371.90M$160.95M23.11360Upcoming EarningsShort Interest ↓IMCRImmunocore3.0457 of 5 stars$29.41+3.5%$63.73+116.7%-49.1%$1.47B$310.20M-30.96320Upcoming EarningsPositive NewsKNSAKiniksa Pharmaceuticals2.4823 of 5 stars$20.05-0.8%$37.17+85.4%+44.1%$1.46B$423.24M-143.20220Earnings ReportAnalyst ForecastNews CoverageIRONDisc Medicine2.3669 of 5 stars$42.06-0.3%$93.80+123.0%+77.5%$1.45BN/A-10.5730Upcoming EarningsNews CoveragePositive NewsSPRYARS Pharmaceuticals3.118 of 5 stars$14.32-3.8%$31.00+116.5%+60.6%$1.41B$89.15M-28.0890Upcoming EarningsNews CoveragePositive NewsHigh Trading VolumeEWTXEdgewise Therapeutics3.239 of 5 stars$13.30-1.1%$40.13+201.7%-8.6%$1.39BN/A-8.8760Upcoming EarningsAnalyst ForecastShort Interest ↑Positive NewsVERAVera Therapeutics2.9478 of 5 stars$21.11-0.8%$64.67+206.3%-40.9%$1.35BN/A-8.0940Upcoming EarningsNews CoveragePositive NewsGap DownTVTXTravere Therapeutics2.8991 of 5 stars$15.11+1.3%$32.08+112.3%+276.3%$1.34B$233.18M-3.69460GPCRStructure Therapeutics2.2247 of 5 stars$23.10+6.2%$81.29+251.9%-31.5%$1.32BN/A-31.22136Upcoming EarningsNews CoveragePositive NewsHigh Trading VolumeMESOMesoblast1.7712 of 5 stars$10.28-4.1%$18.00+75.1%+72.7%$1.31B$5.67M0.0080Gap DownEVOEvotec1.8551 of 5 stars$3.58-0.6%$5.93+65.7%-19.1%$1.27B$777.05M0.004,200Upcoming EarningsShort Interest ↓Gap Down Related Companies and Tools Related Companies Immunocore Alternatives Kiniksa Pharmaceuticals Alternatives Disc Medicine Alternatives ARS Pharmaceuticals Alternatives Edgewise Therapeutics Alternatives Vera Therapeutics Alternatives Travere Therapeutics Alternatives Structure Therapeutics Alternatives Mesoblast Alternatives Evotec Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KMDA) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kamada Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kamada With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KMDA Stock Free KMDA Stock Alerts